Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI‐mediated basophil activation by a tumour‐specific IgE antibody to evaluate the risk of type I hypersensitivity

Sarah Maria Rudman, Sophia N. Karagiannis, Helen Cambrook et al.|Clinical & Experimental Allergy|2011

Cited by 41